Inhibition
of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach
to treat tau pathology in neurodegenerative diseases such as Alzheimer’s
disease and progressive supranuclear palsy. Beginning with carbohydrate-based
lead molecules, we pursued an optimization strategy of reducing polar
surface area to align the desired drug-like properties of potency,
selectivity, high central nervous system (CNS) exposure, metabolic
stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic
response. Herein, we describe the medicinal chemistry and pharmacological
studies that led to the identification of (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol 42 (MK-8719), a highly potent and selective OGA inhibitor
with excellent CNS penetration that has been advanced to first-in-human
phase I clinical trials.
The condensation of aldehydes, beta-keto esters and urea catalyzed by NH(2)SO(3)H in ethanol results dihydropyrimidinones in high yields under ultrasound irradiation.
Based on the attrition rate of CCR5 small molecule antagonists in the clinic the discovery and development of next generation antagonists with an improved pharmacology and safety profile is necessary. Herein, we describe a combined molecular modeling, CCR5-mediated cell fusion, and receptor site-directed mutagenesis approach to study the molecular interactions of six structurally diverse compounds (aplaviroc, maraviroc, vicriviroc, TAK-779, SCH-C and a benzyloxycarbonyl-aminopiperidin-1-yl-butane derivative) with CCR5, a coreceptor for CCR5-tropic HIV-1 strains. This is the first study using an antifusogenic assay, a model of the interaction of the gp120 envelope protein with CCR5. This assay avoids the use of radioactivity and HIV infection assays, and can be used in a high throughput mode. The assay was validated by comparison with other established CCR5 assays. Given the hydrophobic nature of the binding pocket several binding models are suggested which could prove useful in the rational drug design of new lead compounds.
Claisen-Schmidt condensation of acetophenone with aromatic aldehydes catalyzed by pulverized KOH and KF-Al2O3 results chalcones in 52-97% and 83-98% yields respectively in alcoholic solvent under ultrasound irradiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.